I. Botev

582 citations
10 papers · 381 indexed · h-index 7
Topics
Immunotherapy and Immune Responses (4 papers)vaccines and immunoinformatics approaches (2 papers)Nonmelanoma Skin Cancer Studies (2 papers)
Partner nations
GermanyBulgariaAustria

In The Last Decade

I. Botev

10 papers receiving 358 citations

Peers

I. Botev
Comparison fields: 5 of 60
  • Immunology 196
  • Oncology 124
  • Molecular Biology 108
  • Epidemiology 91
  • Dermatology 73
Replace Marianne Niin with:
Marianne Niin Germany
Muriel Nguyen Belgium
Tatjana Scholz Germany
Gary Lam United States
Aswani Vunnava United States
Gabriel E. Molina United States
F. Villard‐Truc France
Karlheinz Enssle Germany
Joana Duarte Portugal
Eric D. Carlsen United States
I. Botev relative to Marianne Niin Germany Marianne Niin's profile →
Citations per field
00.5×1.5×2.1×
Marianne Niin · 1×
Citations per year

Countries citing papers authored by I. Botev

Since Specialization
Citations

This map shows the geographic impact of I. Botev's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Botev with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Botev more than expected).

Fields of papers citing papers by I. Botev

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Botev. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Botev. The network helps show where I. Botev may publish in the future.

Co-authorship network of co-authors of I. Botev

This figure shows the co-authorship network connecting the top 25 collaborators of I. Botev. A scholar is included among the top collaborators of I. Botev based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Botev. I. Botev is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
#WorkIndexed citations
1 3
2 2
3 79
4 1
5 60
6 59
7 68
8 46
9
Infections and melanoma risk: results of a multicentre EORTC case-control study. European Organization for Research and Treatment of Cancer.
50
10 13

About I. Botev

I. Botev is a scholar working on Immunology, Otorhinolaryngology and Dermatology, having authored 10 papers that have together received 381 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (4 papers), vaccines and immunoinformatics approaches (2 papers) and Nonmelanoma Skin Cancer Studies (2 papers). The work is most often cited by research in Immunology (196 citations), Dermatology (73 citations) and Oncology (124 citations). I. Botev has collaborated with scholars based in Germany, Bulgaria and Austria. Frequent co-authors include Olaf Gefeller, C Seebacher, Annette Pfahlberg, Raphael Shafir, E. M. Kokoschka, Marianne Niin, D Lambert, Ulrich R. Kleeberg, B. M. Henz and K.F. Kölmel. Their work appears in journals such as Frontiers in Immunology, Journal of Investigative Dermatology and European Journal of Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026